# Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC

> **NCT03181308** · PHASE1 · COMPLETED · sponsor: **Tracon Pharmaceuticals Inc.** · enrollment: 11 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Carotuximab (TRC105)
- **DRUG:** OPDIVO

## Key facts

- **NCT ID:** NCT03181308
- **Lead sponsor:** Tracon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-09
- **Primary completion:** 2019-07-22
- **Final completion:** 2019-07-22
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2020-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03181308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03181308, "Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03181308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*